Aerovate Therapeutics, Inc. [AVTE] Filings

10-Q 1 tmb-20240930x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission File Number: 001-40544

AEROVATE THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	83-1377888
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

930 Winter Street, Suite M-500
Waltham, MA	02451
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (617) 443-2400

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	AVTE	The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 8, 2024, the registrant had 28,874,513 shares of common stock, $0.0001 par value per share, outstanding.

Table of Contents


		Page
PART I.	FINANCIAL INFORMATION	6
Item 1.	Financial Statements (Unaudited)	6
	Condensed Consolidated Balance Sheets	6
	Condensed Consolidated Statements of Operations and Comprehensive Loss	7
	Condensed Consolidated Statements of Stockholders’ Equity	8
	Condensed Consolidated Statements of Cash Flows	10
	Notes to Unaudited Condensed Consolidated Financial Statements	11
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31
Item 4.	Controls and Procedures	31

PART II.	OTHER INFORMATION	32
Item 1.	Legal Proceedings	32
Item 1A.	Risk Factors	32
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	63
Item 3.	Defaults Upon Senior Securities	63
Item 4.	Mine Safety Disclosures	63
Item 5.	Other Information	63
Item 6.	Exhibits	64
	Signatures	66

Table of Contents

SUMMARY OF THE MATERIAL AND OTHER RISKS ASSOCIATED WITH OUR BUSINESS

Our business is subject to numerous material and other risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following:

●

We may not be successful in consummating the Merger.

●

If we are successful in completing the Merger, we may be exposed to other operational and financial risks.

●

If the Merger is not completed, our board of directors may pursue a dissolution and liquidation. In such event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation and the amount of cash that will need to be reserved for commitments and contingent liabilities.

●

Failure to complete the Merger may result in either Jade or us paying a termination fee to the other party and could harm our common stock price and the future business and operations of each company.

●

Some of Jade’s and our executive officers and directors have interests in the Merger that are different from yours.

●

We are a biopharmaceutical company with a limited operating history.

●

We have incurred significant operating losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We may never achieve or maintain profitability.

●

We have no products approved for commercial sale and have not generated any revenue from product sales.

●

The results of earlier studies and trials may not be predictive of future trial results.

●

We have six issued U.S. patents and many pending patent applications with respect to AV-101, however, we have begun the process of abandoning our patent estate and we are no longer prosecuting our patent applications. Further, we can provide no assurance that any of our future patent applications will result in issued patents. If we cannot protect our patent rights or our other proprietary rights, others may develop products similar or identical to ours, and we may not be able to compete effectively in our market or successfully commercialize any product candidates we may develop.

●

We may be unable to obtain regulatory approval under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of any product candidates and adversely impact our potential to generate revenue, our business and our results of operations.

●

Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.

The material and other risks summarized above should be read together with the text of the full risk factors below and in the other information set forth in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and the related notes, as well as in other documents that we file with the U.S. Securities and Exchange Commission, or the SEC. If any such material and other risks and uncertainties actually occur, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks summarized above or described in full under Item 1A of this Quarterly Report on Form 10-Q are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, prospects, financial condition and results of operations.

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains express or implied forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

●

anticipated expenses and cost savings in connection with our discontinuation of development of AV-101;

●

the proposed merger with Jade Biosciences, Inc., and related transactions;

●

estimates of our future expenses, revenues, capital requirements and our needs for additional financing;

●

our expectations for clinical and regulatory development plans;

●

our expectations regarding our ability to obtain and maintain intellectual property protection for any product candidates we may develop;

●

our ability to identify products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;

●

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, including the projected terms of patent protection;

●

potential regulatory developments in the United States and foreign countries;

●

developments relating to our competitors and our industry, including the impact of government laws and regulations;

●

our ability to retain key management personnel in order to operate our business following announcement of our workforce reduction plan and the proposed merger with Jade Biosciences, Inc., and related transactions;

●

our ability to obtain additional funding for our operations, if needed, should we decide to pursue development of other product candidates; and

●

other risks and uncertainties, including those listed under the section titled “Risk Factors.”

In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed above under “Summary of the Material Risks Associated with Our Business” and under the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the Securities and Exchange Commission, or the SEC, as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.

Table of Contents

The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.

This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this Quarterly Report on Form 10-Q, their estimates, in particular as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q.

Table of Contents

PART I-FINANCIAL INFORMATION

Item 1. Financial Statements.

Aerovate Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(in thousands, except share and per share amounts)


	September 30,		December 31,
	2024		2023
Assets
Current assets:
Cash and cash equivalents	$	31,115	$	23,491
Short-term investments		57,615		98,948
Prepaid expenses and other current assets		1,875		1,793
Total current assets		90,605		124,232
Property and equipment, net		14		288
Operating lease right-of-use assets		259		614
Other long-term assets		81		2,284
Total assets	$	90,959	$	127,418

Liabilities and Stockholders’ Equity

Current liabilities:
Accounts payable	$	908	$	2,396
Accrued and other current liabilities		8,948		14,821
Operating lease liabilities		459		420
Total current liabilities		10,315		17,637
Operating lease liabilities, net of current portion		81		255
Other liabilities		70		70
Total liabilities		10,466		17,962

Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; no shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively		—		—
Common stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 28,867,711 and 27,762,703 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively		3		3
Additional paid-in capital		307,888		272,640
Accumulated other comprehensive gain		224		237
Accumulated deficit		(227,622)		(163,424)
Total stockholders’ equity		80,493		109,456
Total liabilities and stockholders’ equity	$	90,959	$	127,418

See accompanying notes to unaudited interim condensed consolidated financial statements.

Table of Contents

Aerovate Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except share and per share amounts)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Operating expenses:
Research and development	$	10,328	$	16,884	$	51,656	$	46,406
General and administrative		7,082		4,484		16,537		12,937
Total operating expenses		17,410		21,368		68,193		59,343
Loss from operations		(17,410)		(21,368)		(68,193)		(59,343)
Other income (expense):
Interest income		1,183		1,804		4,014		4,236
Other expense:		(10)		1		(19)		(1)
Total other income		1,173		1,805		3,995		4,235
Net loss	$	(16,237)	$	(19,563)	$	(64,198)	$	(55,108)
Comprehensive loss:
Net loss	$	(16,237)	$	(19,563)	$	(64,198)	$	(55,108)
Other comprehensive loss:
Unrealized (loss) gain on securities		307		(22)		(13)		243
Comprehensive loss	$	(15,930)	$	(19,585)	$	(64,211)	$	(54,865)
Net loss per share, basic and diluted	$	(0.56)	$	(0.71)	$	(2.25)	$	(2.13)
Weighted-average shares of common stock outstanding, basic and diluted		28,863,327		27,640,542		28,572,338		25,872,118

See accompanying notes to unaudited interim condensed consolidated financial statements.

Table of Contents

Aerovate Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(in thousands, except share amounts)



						Accumulated
				Additional		Other				Total
	Common Stock			Paid-In		Comprehensive		Accumulated		Stockholders’
	Shares	Amount		Capital		Gain/(Loss)		Deficit		Equity
Balance at December 31, 2023	27,762,703	$	3	$	272,640	$	237	$	(163,424)	$	109,456
Unrealized loss on investments	—		—		—		(270)		—		(270)
Issuance of common stock upon exercise of stock options	133,282		—		704		—		—		704
Vesting of restricted stock units	2,776		—		—		—		—		—
Stock based compensation	—		—		4,200		—		—		4,200
Net loss	—		—		—		—		(23,186)		(23,186)
Balance at March 31, 2024	27,898,761	$	3	$	277,544	$	(33)	$	(186,610)	$	90,904
Unrealized loss on investments	—		—		—		(50)		—		(50)
Issuance of common stock in connection with ATM, net	800,000		—		23,635		—		—		23,635
Issuance of common stock upon exercise of stock options	119,239		—		511		—		—		511
Issuance of common stock under ESPP	34,034		—		308		—		—		308
Vesting of restricted stock units	2,716		—		—		—		—		—
Stock based compensation	—		—		3,865		—		—		3,865
Net loss	—		—		—		—		(24,775)		(24,775)
Balance at June 30, 2024	28,854,750	$	3	$	305,863	$	(83)	$	(211,385)	$	94,398
Unrealized gain on investments	—		—		—		307		—		307
Issuance of common stock upon exercise of stock options	12,961		—		22		—		—		22
Stock based compensation	—		—		2,003		—		—		2,003
Net loss	—		—		—		—		(16,237)		(16,237)
Balance at September 30, 2024	28,867,711	$	3	$	307,888	$	224	$	(227,622)	$	80,493

Table of Contents



						Accumulated
				Additional		Other				Total
	Common Stock			Paid-In		Comprehensive		Accumulated		Stockholders’
	Shares	Amount		Capital		Gain/(Loss)		Deficit		Equity
Balance at December 31, 2022	24,722,974	$	2	$	215,110	$	(466)	$	(87,903)	$	126,743
Unrealized gain on investments	—		—		—		265		—		265
Issuance of common stock upon exercise of stock options	93,966		—		223		—		—		223
Stock based compensation	—		—		2,384		—		—		2,384
Net loss	—		—		—		—		(16,520)		(16,520)
Balance at March 31, 2023	24,816,940	$	2	$	217,717	$	(201)	$	(104,423)	$	113,095
Unrealized loss on investments	—		—		—		(22)		—		(22)
Issuance of common stock in connection with ATM, net	2,662,721		1		44,282		—		—		44,283
Issuance of common stock upon exercise of stock options	106,756		—		333		—		—		333
Issuance of common stock under ESPP	13,866		—		228		—		—		228
Vesting of restricted stock units	815		—				—		—		—
Stock based compensation	—		—		3,034		—		—		3,034
Net loss	—		—		—		—		(19,025)		(19,025)
Balance at June 30, 2023	27,601,098	$	3	$	265,594	$	(223)	$	(123,448)	$	141,926
Unrealized gain on investments	—		—		—		28		—		28
Issuance of common stock upon exercise of stock options	46,777		—		95		—		—		95
Vesting of restricted stock units	5,312		—		—		—		—		—
Stock based compensation	—		—		3,237		—		—		3,237
Net loss	—		—		—		—		(19,563)		(19,563)
Balance at September 30, 2023	27,653,187	$	3	$	268,926	$	(195)	$	(143,011)	$	125,723

See accompanying notes to unaudited interim condensed consolidated financial statements.

Table of Contents

Aerovate Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)


	Nine months ended September 30,
	2024		2023
Cash flow from operating activities:
Net loss	$	(64,198)	$	(55,108)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		10,068		8,655
Depreciation and amortization expense		274		68
Accretion of discounts and amortization of premiums on investments, net		(1,912)		(2,118)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(82)		(128)
Other long-term assets		789		(70)
Accounts payable		(1,488)		880
Accrued and other liabilities		(4,152)		5,948
Operating lease assets and liabilities, net		220		9
Other liabilities		332		(114)
Net cash used in operating activities	$	(60,149)	$	(41,978)

Cash flow from investing activities:
Purchases of short-term investments		(19,683)		(96,194)
Maturities of short-term investments		62,583		102,500
Purchases of property and equipment		—		(78)
Net cash provided by investing activities	$	42,900	$	6,228

Cash flow from financing activities:
Proceeds from sale of common stock in connection with ATM, net		23,635		44,888
Payments for offering costs		(307)		(234)
Proceeds from issuance of common stock under ESPP		308		228
Proceeds from issuance of common stock upon exercise of stock options		1,237		651
Net cash provided by financing activities	$	24,873	$	45,533

Net increase in cash and cash equivalents		7,624		9,783
Cash and cash equivalents at the beginning of the year		23,491		22,397
Cash and cash equivalents at the end of the period	$	31,115	$	32,180

Supplemental disclosure of noncash investing and financing activities:
Right-of-use asset obtained in exchange for operating lease liability	$	206	$	—
Purchases of property and equipment in accounts payable and accrued liabilities	$	—	$	64

See accompanying notes to unaudited interim condensed consolidated financial statements.

Table of Contents

AEROVATE THERAPEUTICS, INC.

NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(1) ORGANIZATION AND NATURE OF OPERATIONS

(a) Organization and Nature of Operations

Aerovate Therapeutics Inc. (“Aerovate” or the “Company”) was incorporated in the state of Delaware in July 2018, and is headquartered in Waltham, Massachusetts. The Company has a wholly owned subsidiary, Aerovate Securities Corporation. The Company is a biopharmaceutical company. The Company’s initial focus was on advancing AV-101, the Company’s dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (“PAH”). However, in June 2024, the Company announced negative results from the Phase 2b portion of its global Phase 2b/Phase 3 trial of AV-101 in adults with PAH, and, as a result, the Company decided to halt enrollment and shut down the Phase 3 portion of the Phase 2b/Phase 3 trial as well as the long-term extension study. In June 2024, the Company announced a corporate restructuring and in July 2024, the Company engaged Wedbush PacGrow as the Company’s exclusive strategic financial advisor to assist in the process of exploring strategic alternatives, including but not limited to an acquisition, merger, reverse merger, business combination, liquidation or other transaction.

On October 30, 2024, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Caribbean Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub I”), Caribbean Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company (“Merger Sub II” and together with Merger Sub I, the “Merger Subs”), and Jade Biosciences, Inc., a Delaware corporation (“Jade”), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, among other things, Merger Sub I will merge with and into Jade, with Jade surviving the merger as the surviving corporation (the “First Merger”), and as part of the same overall transaction, Jade will merge with and into Merger Sub II, with Merger Sub II continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the “Second Merger” and together with the First Merger, the “Merger”). In addition, in connection with the closing of the Merger (the “Closing”), the Company expects to declare a cash dividend to its pre-Merger stockholders of approximately $65.0 million in the aggregate (the “Cash Dividend”), provided such amount is subject to adjustment as set forth in the Merger Agreement. The Merger was approved by the Company’s board of directors (the “Board”), and the Board resolved to recommend approval of the Merger Agreement to the Company’s stockholders. The Closing is subject to approval by the stockholders of the Company and Jade as well as other customary closing conditions, including the effectiveness of a registration statement filed with the U.S. Securities and Exchange Commission (“SEC”) in connection with the transaction. If the Merger is completed, the business of Jade will continue as the business of the combined company.

(b) At-the-Market Offering

On April 5, 2023, the Company entered into an ATM Equity Offering^SM Sales Agreement (the “Sales Agreement”) with BofA Securities, Inc., or the Agent, pursuant to which the Company can sell, from time to time, at its option, up to an aggregate of $75.0 million of shares of its common stock, through the Agent, as its sales agent. As of September 30, 2024, 3,462,721 shares have been sold under the Sales Agreement, generating $67.9 million of net proceeds after deducting commissions to the Agent and other offering costs. As of the date of this Quarterly Report on Form 10-Q, up to $6.0 million of shares of the Company’s common stock remain available for sale from time to time under the Sales Agreement.

Since inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations and has not realized revenues from its planned principal operations. The Company has incurred losses and negative cash flows from operations since

Table of Contents

inception. As of September 30, 2024, the Company had cash and cash equivalents and short-term investments of $88.7 million.

Management believes that the Company’s current cash and cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve months from the filing date of this report while it explores strategic alternatives.

(2) BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023 have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States of America for interim financial information and pursuant to Article 10 of Regulation S-X of the Securities Act of 1933, as amended (the Securities Act). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company’s financial position and the results of its operations and cash flows.

The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results expected for the full fiscal year or any subsequent interim period. The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by GAAP for complete financial statements. Because all of the disclosures required by GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the notes accompanying them should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

(b) Use of Estimates

The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company’s potentially dilutive securities have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per

Table of Contents

share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

The following table summarizes the Company’s net loss per share (in thousands, except share and per share amounts):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Numerator:
Net loss	$	(16,237)	$	(19,563)	$	(64,198)	$	(55,108)
Net loss attributable to common stockholders	$	(16,237)	$	(19,563)	$	(64,198)	$	(55,108)

Denominator:
Weighted-average common stock outstanding, basic and diluted		28,863,327		27,640,542		28,572,338		25,872,118
Net loss per share, basic and diluted	$	(0.56)	$	(0.71)	$	(2.25)	$	(2.13)

Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):


	As of September 30,
	2024	2023
Options to purchase common stock	3,714,104	5,236,832
Unvested restricted stock units	—	25,754
	3,714,104	5,262,586

(d) Recently Issued and Recently Adopted Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments’ significant expenses on an interim and annual basis. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Entities must adopt the changes to the segment reporting guidance on a retrospective basis, and early adoption is permitted. The Company does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity’s income tax rate reconciliation table and regarding cash taxes paid both in the U.S. and foreign jurisdictions. The standard is effective for fiscal years beginning after December 15, 2024, and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard may have on its consolidated financial statements and related disclosures, and does not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.

Table of Contents

(3) FAIR VALUE OF FINANCIAL INSTRUMENTS

The following tables summarize the Company’s financial assets measured at fair value on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):


			Fair Value Measurements Using
			Quoted Prices in
			Active Markets		Significant Other		Significant
			for Identical		Observable		Unobservable
	September 30,		Assets		Inputs		Inputs
	2024		(Level 1)		(Level 2)		(level 3)
Assets:
Cash equivalents
Money market funds	$	28,265	$	28,265	$	—	$	—
Total cash equivalents		28,265		28,265		—		—

Short-term investments
Agency bonds		27,168		—		27,168		—
Corporate debt securities		11,926		—		11,926		—
Commercial paper		9,443		—		9,443		—
U.S. Treasury bills		9,078		9,078		—		—
Total short-term investments		57,615		9,078		48,537		—

Total fair value of assets	$	85,880	$	37,343	$	48,537	$	—


			Fair Value Measurements Using
			Quoted Prices in
			Active Markets		Significant Other		Significant
			for Identical		Observable		Unobservable
	December 31,		Assets		Inputs		Inputs
	2023		(Level 1)		(Level 2)		(level 3)
Assets:
Cash equivalents
Money market funds	$	19,787	$	19,787	$	—	$	—
Total cash equivalents		19,787		19,787		—		—

Short-term investments
Agency bonds		42,255		—		42,255		—
Commercial paper		38,386		—		38,386		—
U.S. Treasury bills		10,362		10,362		—		—
Corporate debt securities		7,945		—		7,945		—
Total short-term investments		98,948		10,362		88,586		—

Total fair value of assets	$	118,735	$	30,149	$	88,586	$	—

Cash Equivalents and Short-Term Investments

Financial assets measured at fair value on a recurring basis consist of the Company’s cash equivalents and short-term investments. Cash equivalents consisted of money market funds and commercial paper, and short-term investments consisted of U.S. Treasury bills, agency bonds, corporate debt securities, and commercial paper. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.

Table of Contents

The following tables summarize the Company’s short-term investments (in thousands):


		As of September 30, 2024
				Gross		Gross
		Amortized		unrealized		unrealized		Estimated fair
	Maturity	cost		gains		losses		value
Agency bonds	1 year or less		27,029		139		—		27,168
Corporate debt securities	1 year or less		11,866		60		—		11,926
Commercial paper	1 year or less		9,438		5		—		9,443
U.S. Treasury bills	1 year or less		9,058		20		—		9,078
		$	57,391	$	224	$	—	$	57,615

As of December 31, 2023

Gross

Aerovate Therapeutics, Inc. [AVTE] Filings
10-Q	[2024-11]
10-Q	[2024-08]
10-Q	[2024-05-13]
10-K	[2024-03-25]
10-Q	[2023-11-13]
10-Q	[2023-08-14]
10-Q	[2023-05-15]
10-K	[2023-03-29]
10-Q	[2022-11-14]
10-Q	[2022-08-15]
10-Q	[2022-05-16]
10-K	[2022-03-30]
10-Q	[2021-11-15]
10-Q	[2021-08-16]
S-1	[2021-06-09]